MUMBAI, India, June 30 -- Intellectual Property India has published a patent application (202641073743 A) filed by Vanga Manav Goud; Charishma Jonnadula; and Manogna Vanga on June 14, 2026, for System And Method For Clinical Decision Support In Antimicrobial Therapy Selection Using A Multi- Layer Decision Control Architecture.
Inventors include Vanga Manav Goud; Charishma Jonnadula; and Manogna Vanga.
The application for the patent was published on June 26, 2026, under issue no. 26/2026.
Abstract: Antimicrobial resistance poses a critical public health threat in India, where resistance rates in common pathogens exceed 50 to 90 percent for first-line drugs. Existing clinical decision tools depend on static guidelines or single-model predictions and do not account for local resistance data, patient-specific safety factors, or the statistical reliability of the underlying evidence. This invention provides a multi-layer clinical decision control architecture for antimicrobial therapy selection. Patient inputs are processed through sequential specialized decision engines that evaluate resistance eligibility, drug safety, host risk factors, geographic resistance confidence, and stewardship policy. The key technical contributions are a triplet-based stewardship exception registry, confidence-gated resistance blocking, hierarchical disease- specific rescue rules, and dynamic decision reliability weighting enforced through a precedence-based combiner. The system produces deterministic, reproducible antibiotic recommendations classified as PREFERRED, ALTERNATIVE, CAUTION, REVIEW_REQUIRED, or AVOID, each accompanied by a structured confidence object that identifies limiting factors. The architecture is validated for the Indian clinical context using ICMR and NARS-Net surveillance data across five geographic regions and four disease modules.
Disclaimer: Curated by HT Syndication.
